The primary objective for this study is to evaluate the safety of and record the full effects of a new human growth hormone for men. The study is randomized, vehicle-controlled, ascending multiple dose, placebo-controlled, clinical proof-of-concept, phase 2 study to evaluate the safety, efficacy, tolerability, pharmacokinetics, pharmacodynamics, and physiological effects of Virilimax® administered subcutaneously in adult male patients. Full nudity of volunteers is required.